Lilly(US:LLY) 智通财经网·2025-09-17 23:23Core Viewpoint - Eli Lilly's diabetes drug Mounjaro shows promising results in helping children as young as 10 control blood sugar and lose weight, potentially providing a new tool for combating childhood diabetes [1][2]. Group 1: Research Findings - Mounjaro demonstrated an average blood sugar reduction of approximately 2% in adolescent patients, with over 10% weight loss after one year of treatment [1]. - The study included around 100 children aged 10 to 17 and has been submitted to global regulatory agencies for expanding Mounjaro's indications [1]. - The research results were published in The Lancet, highlighting the urgent need for effective treatment options for childhood type 2 diabetes [2]. Group 2: Market Context - The prevalence of type 2 diabetes among youth has doubled from 2002 to 2018, with nearly one-third of adolescents showing prediabetic symptoms [3]. - Approximately 20% of children aged 6 and older are affected by obesity, prompting calls for more aggressive intervention measures [3]. - Eli Lilly's Mounjaro and Zepbound are currently only approved for adult patients, while competitors like Novo Nordisk are conducting trials for younger populations [2]. Group 3: Safety and Efficacy Concerns - Concerns exist regarding the safety and efficacy of GLP-1 drugs in children, with some experts advocating for behavioral therapy as a first-line treatment [3][4]. - The study found no significant differences in growth rates between children using Mounjaro and those on a placebo, although 15% of Mounjaro users experienced hypoglycemia [3]. - The U.S. Department of Health and Human Services has raised concerns about the potential over-medicalization of children with these drugs [4].